Sarepta Therapeutics, Inc.SRPT

Sarepta Therapeutics closed its latest SEC filing with a net income of $331.0 million for the quarter ended 31 March 2026, but the income statement is only half the story. The company’s cash and cash equivalents fell to $464.4 million while operating cash flow printed a negative $202.7 million, a gap that the $69.8 million inventory build and $2.1 million of capital expenditure do not fully explain. The contrast between the net income number and the cash position raises a simple question: where did the cash go?

Sarepta’s sole FDA-approved gene therapy, ELEVIDYS (delandistrogene moxeparvovec-rokl), received accelerated approval in June 2023 for ambulatory Duchenne patients aged four through five, but the product’s revenue contribution is now tangled with $1.00 billion of inventory sitting on the balance sheet as of 31 March 2026. The company’s pipeline page showcases a long list of RNA-based and gene-therapy programs, yet the SEC filings confirm no single country outside the U.S. exceeds 10% of net product revenues, underscoring the company’s reliance on a single product and a single market. The clinical trials rail lists ongoing studies, but the only financial link back to those trials is the inventory line-and that line has grown faster than the cash.

According to the 10-Q filed 6 May 2026, total revenues reached $730.8 million for the quarter, with $330.5 million booked under “Revenue from Contract with Customer, Excluding Assessed Tax.” Net income attributable to the parent was $331.0 million, and diluted earnings per share clocked in at $2.88 on 121.9 million diluted shares outstanding. Assets stood at $3.18 billion against liabilities of $1.67 billion, leaving shareholders’ equity at $1.51 billion. Operating income was $358.4 million, but operating cash flow was negative $202.7 million, with capital expenditure a trivial $2.1 million and inventory up $69.8 million. Cash and cash equivalents were $464.4 million and short-term investments were $188.7 million. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/873303/000119312526208893/srpt-20260331.htm)

The company’s product and pipeline rail frames Sarepta as a gene-therapy pioneer with RNA-based treatments already on the U.S. market and more on the way, but the evidence on the balance sheet tells a quieter tale. The industry-leading pipeline touted on the website currently lists one gene therapy and three RNA-based therapies on the market in the United States as of April 2026, yet the revenue concentration and inventory buildup suggest the “industry-leading” label has not yet translated into diversified cash generation. The clinical trials page is a catalogue of trials dating back to January 2020, but the only concrete financial bridge from those trials to the income statement is the inventory line, which is now larger than many biotech companies’ entire market capitalisation. (source: Sarepta products and pipeline rail, https://www.sarepta.com/products-pipeline)

For readers tracking the gap between the polished story and the cash reality, the next filing that matters will be the Q2 2026 10-Q, due in early August. That document will reveal whether the negative operating cash flow has reversed or whether the inventory build has continued its march north of a billion dollars. Until then, Sarepta’s balance sheet is the only reliable source of truth-and it is currently telling a story that is less about breakthrough therapies and more about inventory management. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=873303)

The company’s submissions JSON on SEC EDGAR lists routine 8-Ks, 10-Qs, and proxy statements, but none of the filings to date materially alter the cash story. The ownership XML filings show no blockbuster insider moves, only the steady accumulation of shares by institutions and the quiet erosion of cash. The product rail and clinical trials rail provide colour and context, but they do not change the numbers: revenue concentration, inventory buildup, and negative operating cash flow remain the defining features of the quarter. (source: SEC EDGAR submissions JSON, https://data.sec.gov/submissions/CIK0000873303.json; SEC ownership XML rail, https://www.sec.gov/Archives/edgar/data/873303/000119312526260263/xslF345X06/ownership.xml)